Cybin (CYBN) News Today → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free CYBN Stock Alerts $0.37 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC Filings All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCybin Provides Corporate Update and Highlights Upcoming Clinical Milestonesfinance.yahoo.com - May 6 at 8:46 AMCybin Provides Corporate Update and Highlights Upcoming Clinical Milestonesbusinesswire.com - May 6 at 8:32 AMCybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistrybusinesswire.com - April 18 at 7:30 AMCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorderbusinesswire.com - April 16 at 7:30 AMCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferencebusinesswire.com - April 10 at 7:30 AMCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferencebusinesswire.com - April 10 at 7:30 AMCybin (OTCMKTS:CYBN) Trading Down 5.3%marketbeat.com - March 29 at 12:57 AM3 Penny Stocks That Could Be Multibaggers in the Making: March Editioninvestorplace.com - March 26 at 2:19 PMCybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Millionbusinesswire.com - March 19 at 11:53 AMCybin to Present at Public Ventures Discovery Day on March 19th in Dallasbusinesswire.com - March 18 at 7:30 AMCybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorderbusinesswire.com - March 15 at 7:30 AMCybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy Ratingmarkets.businessinsider.com - March 14 at 6:22 PMCybin to begin Phase 3 study for psychedelic drug mid-yearmsn.com - March 14 at 1:21 PMBuy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA Designationsmarkets.businessinsider.com - March 14 at 8:20 AMCybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Designbusinesswire.com - March 14 at 7:30 AMCybin Gets Breakthrough Therapy Designation For Its Psychedelic-based Therapeutic CYB003markets.businessinsider.com - March 13 at 7:03 AMCybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorderbusinesswire.com - March 13 at 6:00 AMCybin to Host Conference Call and Webcast to Provide Program Update for CYB003businesswire.com - March 12 at 10:37 PM3 High-Potential Penny Stocks to Turn $1000 into $1 millioninvestorplace.com - March 10 at 5:00 PMCybin to Present at the TD Cowen 44th Annual Health Care Conferencebusinesswire.com - February 27 at 7:30 AMCybin Inc.thestreet.com - February 16 at 8:39 AMCybin Reports Third Quarter Financial Results and Recent Business Highlightsfinance.yahoo.com - February 14 at 8:46 AMCybin Reports Third Quarter Financial Results and Recent Business Highlightsbusinesswire.com - February 14 at 7:45 AMCybin (OTCMKTS:CYBN) Trading Up 10.8%marketbeat.com - February 13 at 3:02 AMCybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Programfinance.yahoo.com - February 7 at 7:51 AMFDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxietymsn.com - January 23 at 2:24 PMCybin gets FDA clearance for Phase 2a study of psychedelic drugmsn.com - January 23 at 2:24 PMCybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorderfinance.yahoo.com - January 23 at 8:57 AMBuy Rating Affirmed for Cybin Based on Advancements in Psychedelic Treatments and Optimistic Valuationmarkets.businessinsider.com - January 5 at 7:57 AMCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Programfinance.yahoo.com - December 6 at 9:57 AMCybin Reports Positive Data From Phase 2 CYB003 In Major Depressive Disordermarkets.businessinsider.com - November 30 at 8:28 AMCybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Dosesfinance.yahoo.com - November 30 at 8:28 AMCybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York Cityfinance.yahoo.com - November 20 at 9:28 AMCybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goalsmsn.com - November 15 at 4:58 PMThinking about buying stock in Tesla Inc, Chevron, Theseus Pharmaceuticals, Cybin Inc, or NXU Inc.?benzinga.com - November 15 at 11:58 AMCybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Dealbenzinga.com - November 10 at 3:40 PMCybin Prices Offering Of About 66.67 Mln Units At $0.45/unitmarkets.businessinsider.com - November 10 at 10:39 AMCybin Inc Ordinary Sharesmorningstar.com - November 8 at 9:00 PMSmall Pharma Obtains Final Order Approving Arrangementfinance.yahoo.com - October 17 at 6:20 PMPsyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & Morebenzinga.com - October 6 at 6:32 PMCybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summitfinance.yahoo.com - October 4 at 8:41 AMCybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorderfinance.yahoo.com - October 3 at 9:18 AMCybin’s Promising Developments and Emerging Data: A Comprehensive Analysis Justifying Buy Rating and $10 Price Targetmarkets.businessinsider.com - October 2 at 1:15 PMCybin to Participate in the Cantor Global Healthcare Conferencefinance.yahoo.com - September 25 at 9:39 AMWall Street Hedge Fund Genius Bets on Cybin Inc.finanznachrichten.de - September 20 at 11:45 PMCybin shares continue to rise on major investment from Steve Cohen's hedge fundproactiveinvestors.com - September 20 at 1:44 PMCybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMTbenzinga.com - September 5 at 5:11 PMCybin Announces Grant of U.S. Patent Covering Deuterated Tryptaminesfinance.yahoo.com - September 5 at 5:11 PMWhat 11 Analyst Ratings Have To Say About Cybinmarkets.businessinsider.com - September 1 at 4:19 PMCybin Buying Small Pharma in All-Stock Transactionmarketwatch.com - August 29 at 6:53 PM Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk Secret Crypto Plot Exposed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. CYBN Media Mentions By Week CYBN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYBN News Sentiment▼0.630.37▲Average Medical News Sentiment CYBN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYBN Articles This Week▼21▲CYBN Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NervGen Pharma News Today BioStem Technologies News Today Incannex Healthcare News Today Global Cord Blood News Today Global Cord Blood News Today Newron Pharmaceuticals News Today Electromed News Today CervoMed News Today BioAtla News Today Cardiff Oncology News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYBN) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
